Biogen Inc. stock price

Biogen Inc. latest news:


  • 01/19/2018 05:42:25

    Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors

    Shares of biotech Acorda Therapeutics Inc. surged 20% in premarket trade Friday, after media reports that Biogen Inc. and others are eyeing the company as a possible takeover target. The speculation has been swirling for more than a week. On Thursday, the company offered preliminary guidance for 2017 sales of $542 million, an increase of approximately 10% from 2016. The FactSet consensus is for sales of $568 million. Chief Executive Ron Cohen said he expects 2018 to be a transformative year and for the company to achieve approval and launch its Inbrija investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking carbidopa/levodopa. Shares have gained 21% in the last 12 months, while the S&P 500 has gained about 24%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/08/2018 09:41:17

    Health-care ETF tumbles as biotechnology stocks weigh

    The largest exchange-traded fund to track the health-care sector fell on Monday, dropping as the biggest declining industry of the day by far. The Health Care Select Sector SPDR ETF was down 0.8%, its biggest one-day percentage drop since Dec. 14. The fund is coming off a four-day rally, and it hit a record on Friday. Biotechnology companies were the biggest drags on the sector on Monday. Celgene Corp. fell 3.2% after it agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion. Separately, Biogen Inc. shares fell 3.9% while those for Regeneron Pharmaceuticals was down 3.1%. The iShares Nasdaq Biotechnology ETF fell 0.8% on Monday. Thus far this year, the health-care fund is up 2.3%, compared with the 2.6% rise of the S&P 500 . The S&P was unchanged in Monday trading.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 13:21:48

    Biogen price target raised 20% to $420 at Instinet, citing 'meaningful 2018 for the company'

    Biogen Inc.'s price target was raised 18% to $420 by Instinet on Thursday, citing its expectation of "a meaningful 2018 for the company." The price target increase comes as Biogen shares have slid 3% after a negative analysis was released for one of its Alzheimer's disease drug trials. Instinet analyst Christopher Marai, however, noted high hopes for the company's spinal muscular atrophy therapy Spinraza, agreements Biogen has with companies like Alkermes and Eisai and the company's much-anticipated other Alzheimer's disease drug, aducanumab. "In our view, potentially positive catalysts from BIIB's both widely covered and underappreciated mid- to late-stage pipeline assets (which we do not yet include in our own estimates) will not only be stock-moving but also index-moving, making BIIB 'a must own name.'" Biogen shares have risen 2.6% over the last three months to $323.23, compared with a 7.5% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 09:07:03

    UPDATE: Biogen shares drop 3% on negative update for Alzheimer's disease drug

    Biogen Inc. shares dropped 3% in morning trade Thursday after the company put out a negative update for its Alzheimer's disease drug. An Independent Data Monitoring Committee's 12-month analysis found that the therapy, BAN2401, "did not meet the criteria for success" based on the trial's primary endpoint. The phase 2 trial will continue through 18 months as planned, with a final analysis at the end, which is expected in the second half of next year. Biogen and Eisai Co. have been partners on BAN2401 since 2014, an agreement that included another Alzheimer's disease drug, E2609, which is also still being developed. Last month, the companies expanded the agreement and, as part of it, eliminated milestone payments for BAN2401. BAN2401's phase 2 trial enrolled 856 patients with early Alzheimer's disease. The Independent Data Monitoring Committee's analysis, called a "Bayesian analysis," was used in the hope that "it would enable us to demonstrate clinical success faster than more traditional study designs," said Lynn Kramer, chief clinical and medical officer of the Eisai Neurology Business Group. The companies emphasized that 16 interim analyses that looked at potential for futility did not find it, and that the Bayesian analysis at 12 months found "success was judged at an 80% of higher probability of achieving a Clinically Significant Difference." Despite the company's Thursday share decline, EvercoreISI analyst Umer Raffat said that the trial wasn't well understood and it shouldn't affect company shares much. "Today, all we learned is that the efficacy delta is ~10%)," Raffat said. "Trial continues to mo 18. This is key." Biogen shares have risen nearly 3% over the last three months, compared with a 7.5% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/21/2017 06:24:15

    Biogen shares drop 4% on negative update for Alzheimer's disease drug

    Biogen Inc. shares dropped 4.1% in premarket trade Thursday after the company put out a negative update for its Alzheimer's disease drug. An Independent Data Monitoring Committee's 12-month analysis found that the therapy, BAN2401, "did not meet the criteria for success" based on the trial's primary endpoint. The phase 2 trial will continue through 18 months as planned, with a final analysis at the end, which is expected in the second half of next year. Biogen and Eisai Co. have been partners on BAN2401 since 2014, an agreement that included another Alzheimer's disease drug, E2609, which is still being developed. Last month, the companies expanded the agreement and, as part of it, eliminated milestone payments for BAN2401. BAN2401's phase 2 trial enrolled 856 patients with early Alzheimer's disease. The Independent Data Monitoring Committee's analysis, called a "Bayesian analysis," was used in the hope that "it would enable us to demonstrate clinical success faster than more traditional study designs," said Lynn Kramer, chief clinical and medical officer of the Eisai Neurology Business Group. The companies emphasized that 16 interim analyses that looked at potential for futility did not find it, and that the Bayesian analysis at 12 months found "success was judged at an 80% of higher probability of achieving a Clinically Significant Difference." Biogen shares have risen 6% over the last three months, compared with a 7% rise in the S&P 500 and a 10.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/19/2017 16:33:19

    BRIEF-Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy

    Biogen Inc(BIIB): * BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY. * BIOGEN WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF THE COLLABORATION. * ‚ÄćIONIS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT AND WILL EARN DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS FROM BIOGEN.

  • 11/27/2017 08:05:35

    Alkermes Could Win Big With New Biogen Partnership


  • 10/24/2017 12:16:54

    UPDATE 4-Biogen dives as Spinraza U.S. sales miss estimates

    * Shares fall as much as 8.14 pct in early trading (Adds details of payment to Neurimmune related to Aducanumab, updates shares)

  • 10/24/2017 09:16:52

    Biogen stock drops 7% on concerns about Spinraza revenue growth

    Biogen Inc. shares plummeted as much as 7% in extremely heavy Tuesday morning trade after Wall Street analysts raised questions about revenue growth for rare disease therapy Spinraza. Though sales of the spinal muscular atrophy therapy came in above analyst expectations, or $271 million compared with the FactSet consensus of $253 million, U.S. sales for the drug barely budged, coming in at $198 million compared with $195 million in the second quarter. (Spinraza was approved late last year.) Mizuho analyst Salim Syed described the growth as "flattish." However, because of $30 million of revenue build in the second quarter, "U.S. sales were not really flat," said Bernstein analyst Ronny Gal. "Our estimate is the rate of new US starts will be relatively stable and this will drive slight but limited US growth," Gal said, adding that it's likely that site capacity is slowing down new starts at existing sites. Biogen's shares declined in Tuesday trade despite reporting third-quarter profit and revenue beats, which EvercoreISI analyst Umer Raffat said "seems a bit overdone to me." Biogen management described Spinraza as a "key current and future growth driver" during its Tuesday third-quarter earnings call. "We expect that Spinraza continues on a strong trajectory in terms of patient uptake in the U.S. and internationally," said Biogen Chief Executive Michel Vounatsos, according to the FactSet earnings transcript. "However, due to the impact of the dosing scheduling, we anticipate Spinraza revenue growth in Q4 will be mostly driven by ex-U.S. markets." Biogen shares have surged 8.9% over the last three months, compared with a 4% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/24/2017 05:09:28

    Biogen posts 18.7 pct jump in quarterly profit

    U.S. drugmaker Biogen Inc (BIIB) on Tuesday reported an 18.7 percent rise in quarterly profit, driven by strong demand for its recently approved spinal muscular atrophy drug, Spinraza. Total revenue rose to $3.08 billion from $2.96 billion.

  • More trends:

    Biolase, Inc.BIOL | BioLife Solutions, Inc.BLFS | BioLineRx Ltd.BLRX | BioMarin Pharmaceutical Inc.BMRN | BiondVax Pharmaceuticals Ltd.BVXV | BiondVax Pharmaceuticals Ltd.BVXVW | Bio-Path Holdings, Inc.BPTH | BioScrip, Inc.BIOS | BioShares Biotechnology Clinical Trials FundBBC | BioShares Biotechnology Products FundBBP |